Neuroprotective Effect of Withaferin Derivatives toward MPP+ and 6‑OHDA Toxicity to Dopaminergic Neurons

Parkinson’s disease is a neurodegenerative proteinopathy that primarily affects mesencephalic dopaminergic neurons. This dopaminergic depletion can be phenotypically reproduced in various experimental models through the administration of two neurotoxins: N-methyl-4-phenylpyridinium (MPP+) and 6-hydr...

Full description

Saved in:
Bibliographic Details
Published inACS chemical neuroscience Vol. 16; no. 5; pp. 802 - 817
Main Authors Parrales, Valeria, Arcile, Guillaume, Laserre, Louise, Normant, Sébastien, Le Goff, Géraldine, Da Costa Noble, Christian, Ouazzani, Jamal, Callizot, Noelle, Haïk, Stéphane, Rabhi, Chérif, Bizat, Nicolas
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 05.03.2025
Subjects
Online AccessGet full text
ISSN1948-7193
1948-7193
DOI10.1021/acschemneuro.4c00655

Cover

Abstract Parkinson’s disease is a neurodegenerative proteinopathy that primarily affects mesencephalic dopaminergic neurons. This dopaminergic depletion can be phenotypically reproduced in various experimental models through the administration of two neurotoxins: N-methyl-4-phenylpyridinium (MPP+) and 6-hydroxydopamine (6-OHDA). The mechanisms underlying the cell death processes induced by these toxins remain a subject of debate. In this context, studies suggest that oxidative-stress-related processes may contribute to the dysfunction and death of dopaminergic neurons. Therefore, investigating pharmacological compounds that can counteract these processes remains crucial for developing therapeutic strategies targeting these neuropathological mechanisms. Withania somnifera (L.) Dunal, commonly known as ashwagandha, is a plant whose roots are used in Ayurvedic medicine to treat various ailments, including those affecting the central nervous system. The active compound Withaferin-A (WFA), a steroid lactone from the withanolide group, is reported to possess antioxidant properties. In this study, we explored the potential neuroprotective effects of WFA and two of its molecular derivatives, cr-591 and cr-777, which contain, respectively, an additional cysteine or glutathione chemical group, known for their antiradical properties. We demonstrated that WFA and its two derivatives, cr-591 and cr-777, protect the integrity and function of dopaminergic neurons exposed to the neurotoxins MPP+ and 6-OHDA both in vitro, using primary mesencephalic neuron cultures from rodents, and in vivo, using the nematode Caenorhabditis elegans.
AbstractList Parkinson's disease is a neurodegenerative proteinopathy that primarily affects mesencephalic dopaminergic neurons. This dopaminergic depletion can be phenotypically reproduced in various experimental models through the administration of two neurotoxins: N-methyl-4-phenylpyridinium (MPP ) and 6-hydroxydopamine (6-OHDA). The mechanisms underlying the cell death processes induced by these toxins remain a subject of debate. In this context, studies suggest that oxidative-stress-related processes may contribute to the dysfunction and death of dopaminergic neurons. Therefore, investigating pharmacological compounds that can counteract these processes remains crucial for developing therapeutic strategies targeting these neuropathological mechanisms. (L.) , commonly known as , is a plant whose roots are used in Ayurvedic medicine to treat various ailments, including those affecting the central nervous system. The active compound ( ), a steroid lactone from the group, is reported to possess antioxidant properties. In this study, we explored the potential neuroprotective effects of and two of its molecular derivatives, and , which contain, respectively, an additional cysteine or glutathione chemical group, known for their antiradical properties. We demonstrated that and its two derivatives, and , protect the integrity and function of dopaminergic neurons exposed to the neurotoxins MPP and 6-OHDA both in vitro, using primary mesencephalic neuron cultures from rodents, and in vivo, using the nematode .
Parkinson’s disease is a neurodegenerative proteinopathy that primarily affects mesencephalic dopaminergic neurons. This dopaminergic depletion can be phenotypically reproduced in various experimental models through the administration of two neurotoxins: N-methyl-4-phenylpyridinium (MPP+) and 6-hydroxydopamine (6-OHDA). The mechanisms underlying the cell death processes induced by these toxins remain a subject of debate. In this context, studies suggest that oxidative-stress-related processes may contribute to the dysfunction and death of dopaminergic neurons. Therefore, investigating pharmacological compounds that can counteract these processes remains crucial for developing therapeutic strategies targeting these neuropathological mechanisms. Withania somnifera (L.) Dunal, commonly known as ashwagandha, is a plant whose roots are used in Ayurvedic medicine to treat various ailments, including those affecting the central nervous system. The active compound Withaferin-A (WFA), a steroid lactone from the withanolide group, is reported to possess antioxidant properties. In this study, we explored the potential neuroprotective effects of WFA and two of its molecular derivatives, cr-591 and cr-777, which contain, respectively, an additional cysteine or glutathione chemical group, known for their antiradical properties. We demonstrated that WFA and its two derivatives, cr-591 and cr-777, protect the integrity and function of dopaminergic neurons exposed to the neurotoxins MPP+ and 6-OHDA both in vitro, using primary mesencephalic neuron cultures from rodents, and in vivo, using the nematode Caenorhabditis elegans.
Parkinson's disease is a neurodegenerative proteinopathy that primarily affects mesencephalic dopaminergic neurons. This dopaminergic depletion can be phenotypically reproduced in various experimental models through the administration of two neurotoxins: N-methyl-4-phenylpyridinium (MPP+) and 6-hydroxydopamine (6-OHDA). The mechanisms underlying the cell death processes induced by these toxins remain a subject of debate. In this context, studies suggest that oxidative-stress-related processes may contribute to the dysfunction and death of dopaminergic neurons. Therefore, investigating pharmacological compounds that can counteract these processes remains crucial for developing therapeutic strategies targeting these neuropathological mechanisms. Withania somnifera (L.) Dunal, commonly known as ashwagandha, is a plant whose roots are used in Ayurvedic medicine to treat various ailments, including those affecting the central nervous system. The active compound Withaferin-A (WFA), a steroid lactone from the withanolide group, is reported to possess antioxidant properties. In this study, we explored the potential neuroprotective effects of WFA and two of its molecular derivatives, cr-591 and cr-777, which contain, respectively, an additional cysteine or glutathione chemical group, known for their antiradical properties. We demonstrated that WFA and its two derivatives, cr-591 and cr-777, protect the integrity and function of dopaminergic neurons exposed to the neurotoxins MPP+ and 6-OHDA both in vitro, using primary mesencephalic neuron cultures from rodents, and in vivo, using the nematode Caenorhabditis elegans.Parkinson's disease is a neurodegenerative proteinopathy that primarily affects mesencephalic dopaminergic neurons. This dopaminergic depletion can be phenotypically reproduced in various experimental models through the administration of two neurotoxins: N-methyl-4-phenylpyridinium (MPP+) and 6-hydroxydopamine (6-OHDA). The mechanisms underlying the cell death processes induced by these toxins remain a subject of debate. In this context, studies suggest that oxidative-stress-related processes may contribute to the dysfunction and death of dopaminergic neurons. Therefore, investigating pharmacological compounds that can counteract these processes remains crucial for developing therapeutic strategies targeting these neuropathological mechanisms. Withania somnifera (L.) Dunal, commonly known as ashwagandha, is a plant whose roots are used in Ayurvedic medicine to treat various ailments, including those affecting the central nervous system. The active compound Withaferin-A (WFA), a steroid lactone from the withanolide group, is reported to possess antioxidant properties. In this study, we explored the potential neuroprotective effects of WFA and two of its molecular derivatives, cr-591 and cr-777, which contain, respectively, an additional cysteine or glutathione chemical group, known for their antiradical properties. We demonstrated that WFA and its two derivatives, cr-591 and cr-777, protect the integrity and function of dopaminergic neurons exposed to the neurotoxins MPP+ and 6-OHDA both in vitro, using primary mesencephalic neuron cultures from rodents, and in vivo, using the nematode Caenorhabditis elegans.
Author Normant, Sébastien
Laserre, Louise
Le Goff, Géraldine
Parrales, Valeria
Callizot, Noelle
Da Costa Noble, Christian
Bizat, Nicolas
Arcile, Guillaume
Rabhi, Chérif
Haïk, Stéphane
Ouazzani, Jamal
AuthorAffiliation AP-HP, Cellule Nationale de Référence des Maladies de Creutzfeldt-Jakob
Neuro-Sys
Faculté de Pharmacie de Paris
Paris Brain Institute, Inserm U1127, CNRS Sorbonne University, Hospital Pitié-Salpêtrière
Paris University
University Hospital Pitié-Salpêtrière
Laboratoire Ethnodyne
AuthorAffiliation_xml – name: University Hospital Pitié-Salpêtrière
– name: AP-HP, Cellule Nationale de Référence des Maladies de Creutzfeldt-Jakob
– name: Laboratoire Ethnodyne
– name: Paris Brain Institute, Inserm U1127, CNRS Sorbonne University, Hospital Pitié-Salpêtrière
– name: Faculté de Pharmacie de Paris
– name: Neuro-Sys
– name: Paris University
Author_xml – sequence: 1
  givenname: Valeria
  surname: Parrales
  fullname: Parrales, Valeria
  organization: Laboratoire Ethnodyne
– sequence: 2
  givenname: Guillaume
  surname: Arcile
  fullname: Arcile, Guillaume
– sequence: 3
  givenname: Louise
  surname: Laserre
  fullname: Laserre, Louise
  organization: Paris Brain Institute, Inserm U1127, CNRS Sorbonne University, Hospital Pitié-Salpêtrière
– sequence: 4
  givenname: Sébastien
  surname: Normant
  fullname: Normant, Sébastien
  organization: Laboratoire Ethnodyne
– sequence: 5
  givenname: Géraldine
  surname: Le Goff
  fullname: Le Goff, Géraldine
– sequence: 6
  givenname: Christian
  surname: Da Costa Noble
  fullname: Da Costa Noble, Christian
  organization: Laboratoire Ethnodyne
– sequence: 7
  givenname: Jamal
  orcidid: 0000-0003-4483-6638
  surname: Ouazzani
  fullname: Ouazzani, Jamal
– sequence: 8
  givenname: Noelle
  surname: Callizot
  fullname: Callizot, Noelle
  organization: Neuro-Sys
– sequence: 9
  givenname: Stéphane
  surname: Haïk
  fullname: Haïk, Stéphane
  organization: University Hospital Pitié-Salpêtrière
– sequence: 10
  givenname: Chérif
  surname: Rabhi
  fullname: Rabhi, Chérif
  email: c.rabhi@ethnodyne.com
  organization: Laboratoire Ethnodyne
– sequence: 11
  givenname: Nicolas
  orcidid: 0000-0001-9643-4417
  surname: Bizat
  fullname: Bizat, Nicolas
  email: nicolas.bizat@icm-institute.org
  organization: Paris University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39946298$$D View this record in MEDLINE/PubMed
BookMark eNp9kc9OGzEQxq0KVCD0DarKx0oowd5d25kjIrRU4t8BxHHl9Y6Lo6yd2rsBbn2FviJPgtOkFScuMyPN7xvr83dAdnzwSMhnziacFfxYm2QesPM4xDCpDGNSiA9kn0M1HSsO5c6beY8cpDTPCLCp_Ej2SoBKFjDdJ_OrtX4ZQ4-mdyukZ9bmiQZL713_oC1G5-ks15Ve7xPtw6OOLb28uTmi2rdUvvz-c30-O6G34ckZ1z9ngs7CUnfOY_zpDP37hE-HZNfqRcJP2z4id9_Obk_PxxfX33-cnlyMdQGqH1tEpTSXuYNqZNsY5A0UFQAThVClqkoFwIWVANAI27bZzLRoBAojWCHLEfm6uZtd_Row9XXnksHFQnsMQ6pLLqWSpYAio1-26NB02NbL6Dodn-t__5OBagOYGFKKaP8jnNXrGOq3MdTbGLKMbWR5W8_DEH02_L7kFc1-j9c
Cites_doi 10.1021/acschemneuro.2c00356
10.1016/j.jchemneu.2020.101752
10.1055/a-1349-3870
10.3390/ijms22168689
10.1002/syn.890150107
10.1038/349414a0
10.3390/ph16020160
10.1093/brain/awab152
10.1016/j.jep.2020.112769
10.1016/j.bcp.2012.08.027
10.2174/0118715249264078231214074107
10.1098/rstb.1986.0056
10.1073/pnas.042497999
10.1016/S0197-0186(96)00025-3
10.1046/j.1471-4159.2002.01000.x
10.1126/science.282.5396.2028
10.1002/ps.3583
10.1016/j.addr.2013.12.001
10.1016/j.steroids.2023.109246
10.1038/35072550
10.1016/j.biopha.2018.06.002
10.1152/physrev.00026.2013
10.3390/cells12091336
10.1002/mnfr.201400014
10.1007/s10495-008-0273-y
10.1016/j.ejmech.2017.09.004
10.3389/fphar.2023.1049334
10.3390/molecules14072373
10.1002/ptr.874
10.1016/0304-3940(88)90705-7
10.3389/fpsyg.2014.01093
10.1016/S0022-3565(25)27139-7
10.1155/2014/768594
10.1016/j.nbd.2021.105256
10.1021/jm00027a021
10.1523/JNEUROSCI.0374-11.2011
10.1038/cr.2008.279
10.1111/bcpt.14011
10.3389/fnins.2020.00303
10.1038/sj.cdd.4402002
10.1248/cpb.50.760
10.1016/j.ejphar.2024.176819
10.1038/nchembio755
10.1248/bpb.b14-00022
10.1046/j.1471-4159.2001.00183.x
10.1207/S15327914NC421_12
10.1007/s10571-006-9003-6
10.1111/j.1471-4159.1992.tb10080.x
10.1016/S0022-3565(25)26555-7
10.3791/59243
10.1016/S0166-4328(89)80121-4
10.3390/ijms25010443
10.1056/nejm198308043090511
10.1016/j.jep.2009.08.003
10.1086/302486
10.1371/journal.pone.0238528
10.1111/j.1476-5381.2010.00725.x
10.1385/JMN/31:02:127
10.1155/2021/9912436
10.1371/journal.pgen.1007106
10.1016/j.exger.2019.110653
10.1523/JNEUROSCI.2992-07.2007
10.1016/0006-291X(86)91211-8
10.1016/S0072-9752(07)83027-2
10.1096/fj.07-095398
10.1038/cdd.2017.186
10.1016/j.steroids.2011.05.012
10.1074/jbc.C500288200
10.1097/00001756-200006260-00035
10.1101/sqb.1983.048.01.049
10.3233/JPD-171258
10.3390/biomedicines11092488
10.18632/oncotarget.20497
10.3390/molecules24244599
10.1016/j.neuint.2016.01.008
10.1016/0024-3205(87)90299-2
10.1016/j.steroids.2022.109172
10.4103/1673-5374.290894
10.1124/mol.106.030015
10.3389/fgene.2012.00048
10.1016/0304-3940(87)90366-1
10.1016/S0378-8741(97)00151-7
10.1016/j.mcn.2016.06.001
10.2478/s11658-007-0015-0
10.1191/0960327105ht509oa
10.4103/0250-474X.95656
10.1159/000080983
10.1007/s11064-014-1443-7
10.1007/BF01271538
10.1016/j.chemosphere.2024.143303
10.3390/ijms22062929
10.1038/nrd1330
10.1016/0012-1606(77)90158-0
10.1016/j.ddtec.2012.02.002
10.1016/S0091-679X(08)61399-0
10.1093/brain/114.5.2283
10.1016/S0301-0082(01)00003-X
ContentType Journal Article
Copyright 2025 American Chemical Society
Copyright_xml – notice: 2025 American Chemical Society
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1021/acschemneuro.4c00655
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 1948-7193
EndPage 817
ExternalDocumentID 39946298
10_1021_acschemneuro_4c00655
a566519098
Genre Journal Article
GroupedDBID ---
53G
55A
5VS
6J9
7~N
AABXI
AAKDD
ABJNI
ABMVS
ABQRX
ABUCX
ACGFO
ACGFS
ACS
ADBBV
ADHLV
AEESW
AENEX
AFEFF
AHGAQ
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
BAANH
BAWUL
CUPRZ
EBS
ED~
F5P
GGK
GNL
GX1
IH9
JG~
OK1
RNS
ROL
RPM
UI2
VF5
VG9
W1F
AAYXX
ABBLG
ABLBI
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-a297t-fee77a16fee97b6dbce1b9249905257374379915f6999b5fdd99482b5e5c50263
IEDL.DBID ACS
ISSN 1948-7193
IngestDate Thu Jul 10 21:56:05 EDT 2025
Fri May 09 01:30:37 EDT 2025
Wed Oct 01 06:50:38 EDT 2025
Thu Mar 06 04:56:18 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords Withaferin A
C. elegans
cr-777
drug discovery
cr-591
neurodegeneration
6-OHDA
MPP
Parkinson’s disease
Language English
License https://doi.org/10.15223/policy-029
https://doi.org/10.15223/policy-037
https://doi.org/10.15223/policy-045
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a297t-fee77a16fee97b6dbce1b9249905257374379915f6999b5fdd99482b5e5c50263
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-4483-6638
0000-0001-9643-4417
PMID 39946298
PQID 3166763592
PQPubID 23479
PageCount 16
ParticipantIDs proquest_miscellaneous_3166763592
pubmed_primary_39946298
crossref_primary_10_1021_acschemneuro_4c00655
acs_journals_10_1021_acschemneuro_4c00655
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2025-03-05
PublicationDateYYYYMMDD 2025-03-05
PublicationDate_xml – month: 03
  year: 2025
  text: 2025-03-05
  day: 05
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle ACS chemical neuroscience
PublicationTitleAlternate ACS Chem. Neurosci
PublicationYear 2025
Publisher American Chemical Society
Publisher_xml – name: American Chemical Society
References ref3/cit3
ref81/cit81
ref16/cit16
ref52/cit52
ref23/cit23
ref2/cit2
ref77/cit77
ref20/cit20
ref48/cit48
ref74/cit74
ref10/cit10
ref35/cit35
ref89/cit89
ref19/cit19
ref93/cit93
ref42/cit42
ref96/cit96
ref13/cit13
ref61/cit61
ref67/cit67
ref38/cit38
ref90/cit90
ref64/cit64
ref54/cit54
ref6/cit6
ref18/cit18
Porter C. C. (ref45/cit45) 1965; 150
ref65/cit65
ref97/cit97
ref11/cit11
ref29/cit29
ref76/cit76
ref86/cit86
ref32/cit32
ref39/cit39
ref5/cit5
Bhattacharya S. K. (ref71/cit71) 1997; 35
ref43/cit43
ref80/cit80
ref28/cit28
ref91/cit91
ref55/cit55
ref12/cit12
ref66/cit66
ref22/cit22
ref33/cit33
ref87/cit87
ref44/cit44
ref70/cit70
ref98/cit98
ref9/cit9
ref27/cit27
ref63/cit63
ref56/cit56
Porter C. C. (ref46/cit46) 1963; 140
ref92/cit92
ref8/cit8
ref31/cit31
ref59/cit59
ref85/cit85
ref34/cit34
ref37/cit37
ref60/cit60
ref88/cit88
ref17/cit17
ref82/cit82
ref53/cit53
ref21/cit21
ref49/cit49
ref75/cit75
ref24/cit24
ref50/cit50
ref78/cit78
ref36/cit36
ref83/cit83
ref79/cit79
ref25/cit25
ref72/cit72
ref14/cit14
ref57/cit57
ref51/cit51
ref40/cit40
ref68/cit68
ref94/cit94
ref26/cit26
ref73/cit73
ref69/cit69
ref15/cit15
ref62/cit62
ref41/cit41
ref58/cit58
ref95/cit95
ref4/cit4
ref30/cit30
ref47/cit47
ref84/cit84
ref1/cit1
ref7/cit7
References_xml – ident: ref35/cit35
  doi: 10.1021/acschemneuro.2c00356
– ident: ref44/cit44
  doi: 10.1016/j.jchemneu.2020.101752
– ident: ref81/cit81
  doi: 10.1055/a-1349-3870
– ident: ref90/cit90
  doi: 10.3390/ijms22168689
– ident: ref54/cit54
  doi: 10.1002/syn.890150107
– ident: ref65/cit65
  doi: 10.1038/349414a0
– ident: ref9/cit9
  doi: 10.3390/ph16020160
– ident: ref25/cit25
  doi: 10.1093/brain/awab152
– ident: ref15/cit15
  doi: 10.1016/j.jep.2020.112769
– ident: ref4/cit4
  doi: 10.1016/j.bcp.2012.08.027
– ident: ref37/cit37
  doi: 10.2174/0118715249264078231214074107
– ident: ref22/cit22
  doi: 10.1098/rstb.1986.0056
– ident: ref29/cit29
  doi: 10.1073/pnas.042497999
– ident: ref77/cit77
  doi: 10.1016/S0197-0186(96)00025-3
– ident: ref85/cit85
  doi: 10.1046/j.1471-4159.2002.01000.x
– ident: ref23/cit23
  doi: 10.1126/science.282.5396.2028
– ident: ref83/cit83
  doi: 10.1002/ps.3583
– ident: ref31/cit31
  doi: 10.1016/j.addr.2013.12.001
– ident: ref8/cit8
  doi: 10.1016/j.steroids.2023.109246
– ident: ref2/cit2
  doi: 10.1038/35072550
– ident: ref49/cit49
  doi: 10.1016/j.biopha.2018.06.002
– ident: ref69/cit69
  doi: 10.1152/physrev.00026.2013
– ident: ref36/cit36
  doi: 10.3390/cells12091336
– ident: ref93/cit93
  doi: 10.1002/mnfr.201400014
– ident: ref76/cit76
  doi: 10.1007/s10495-008-0273-y
– ident: ref6/cit6
  doi: 10.1016/j.ejmech.2017.09.004
– ident: ref11/cit11
  doi: 10.3389/fphar.2023.1049334
– ident: ref70/cit70
  doi: 10.3390/molecules14072373
– ident: ref78/cit78
  doi: 10.1002/ptr.874
– ident: ref59/cit59
  doi: 10.1016/0304-3940(88)90705-7
– ident: ref86/cit86
  doi: 10.3389/fpsyg.2014.01093
– volume: 150
  start-page: 17
  issue: 1
  year: 1965
  ident: ref45/cit45
  publication-title: J. Pharmacol. Exp. Ther.
  doi: 10.1016/S0022-3565(25)27139-7
– ident: ref88/cit88
  doi: 10.1155/2014/768594
– ident: ref34/cit34
  doi: 10.1016/j.nbd.2021.105256
– ident: ref95/cit95
  doi: 10.1021/jm00027a021
– ident: ref87/cit87
  doi: 10.1523/JNEUROSCI.0374-11.2011
– ident: ref56/cit56
  doi: 10.1038/cr.2008.279
– ident: ref38/cit38
  doi: 10.1111/bcpt.14011
– ident: ref48/cit48
  doi: 10.3389/fnins.2020.00303
– ident: ref75/cit75
  doi: 10.1038/sj.cdd.4402002
– ident: ref80/cit80
  doi: 10.1248/cpb.50.760
– ident: ref3/cit3
  doi: 10.1016/j.ejphar.2024.176819
– ident: ref14/cit14
  doi: 10.1038/nchembio755
– ident: ref13/cit13
  doi: 10.1248/bpb.b14-00022
– ident: ref52/cit52
  doi: 10.1046/j.1471-4159.2001.00183.x
– ident: ref73/cit73
  doi: 10.1207/S15327914NC421_12
– ident: ref24/cit24
  doi: 10.1007/s10571-006-9003-6
– ident: ref64/cit64
  doi: 10.1111/j.1471-4159.1992.tb10080.x
– volume: 140
  start-page: 308
  year: 1963
  ident: ref46/cit46
  publication-title: J. Pharmacol. Exp. Ther.
  doi: 10.1016/S0022-3565(25)26555-7
– ident: ref40/cit40
  doi: 10.3791/59243
– ident: ref55/cit55
  doi: 10.1016/S0166-4328(89)80121-4
– ident: ref26/cit26
  doi: 10.3390/ijms25010443
– ident: ref51/cit51
  doi: 10.1056/nejm198308043090511
– ident: ref17/cit17
  doi: 10.1016/j.jep.2009.08.003
– ident: ref97/cit97
  doi: 10.1086/302486
– ident: ref92/cit92
  doi: 10.1371/journal.pone.0238528
– ident: ref30/cit30
  doi: 10.1111/j.1476-5381.2010.00725.x
– ident: ref50/cit50
  doi: 10.1385/JMN/31:02:127
– ident: ref68/cit68
  doi: 10.1155/2021/9912436
– ident: ref47/cit47
  doi: 10.1371/journal.pgen.1007106
– ident: ref89/cit89
  doi: 10.1016/j.exger.2019.110653
– ident: ref41/cit41
  doi: 10.1523/JNEUROSCI.2992-07.2007
– ident: ref61/cit61
  doi: 10.1016/0006-291X(86)91211-8
– ident: ref67/cit67
  doi: 10.1016/S0072-9752(07)83027-2
– ident: ref32/cit32
  doi: 10.1096/fj.07-095398
– ident: ref57/cit57
  doi: 10.1038/cdd.2017.186
– ident: ref5/cit5
  doi: 10.1016/j.steroids.2011.05.012
– ident: ref96/cit96
  doi: 10.1074/jbc.C500288200
– ident: ref79/cit79
  doi: 10.1097/00001756-200006260-00035
– ident: ref20/cit20
  doi: 10.1101/sqb.1983.048.01.049
– ident: ref33/cit33
  doi: 10.3233/JPD-171258
– ident: ref62/cit62
  doi: 10.3390/biomedicines11092488
– ident: ref10/cit10
  doi: 10.18632/oncotarget.20497
– ident: ref19/cit19
  doi: 10.3390/molecules24244599
– ident: ref42/cit42
  doi: 10.1016/j.neuint.2016.01.008
– ident: ref60/cit60
  doi: 10.1016/0024-3205(87)90299-2
– ident: ref7/cit7
  doi: 10.1016/j.steroids.2022.109172
– ident: ref12/cit12
  doi: 10.4103/1673-5374.290894
– ident: ref74/cit74
  doi: 10.1124/mol.106.030015
– ident: ref91/cit91
  doi: 10.3389/fgene.2012.00048
– ident: ref58/cit58
  doi: 10.1016/0304-3940(87)90366-1
– ident: ref72/cit72
  doi: 10.1016/S0378-8741(97)00151-7
– ident: ref53/cit53
  doi: 10.1016/j.mcn.2016.06.001
– ident: ref18/cit18
  doi: 10.2478/s11658-007-0015-0
– volume: 35
  start-page: 297
  issue: 3
  year: 1997
  ident: ref71/cit71
  publication-title: Indian J. Exp. Biol.
– ident: ref16/cit16
  doi: 10.1191/0960327105ht509oa
– ident: ref84/cit84
  doi: 10.4103/0250-474X.95656
– ident: ref27/cit27
  doi: 10.1159/000080983
– ident: ref82/cit82
  doi: 10.1007/s11064-014-1443-7
– ident: ref63/cit63
  doi: 10.1007/BF01271538
– ident: ref94/cit94
  doi: 10.1016/j.chemosphere.2024.143303
– ident: ref39/cit39
  doi: 10.3390/ijms22062929
– ident: ref66/cit66
  doi: 10.1038/nrd1330
– ident: ref21/cit21
  doi: 10.1016/0012-1606(77)90158-0
– ident: ref28/cit28
  doi: 10.1016/j.ddtec.2012.02.002
– ident: ref98/cit98
  doi: 10.1016/S0091-679X(08)61399-0
– ident: ref1/cit1
  doi: 10.1093/brain/114.5.2283
– ident: ref43/cit43
  doi: 10.1016/S0301-0082(01)00003-X
SSID ssj0069086
Score 2.380019
Snippet Parkinson’s disease is a neurodegenerative proteinopathy that primarily affects mesencephalic dopaminergic neurons. This dopaminergic depletion can be...
Parkinson's disease is a neurodegenerative proteinopathy that primarily affects mesencephalic dopaminergic neurons. This dopaminergic depletion can be...
SourceID proquest
pubmed
crossref
acs
SourceType Aggregation Database
Index Database
Publisher
StartPage 802
SubjectTerms 1-Methyl-4-phenylpyridinium - toxicity
Animals
Caenorhabditis elegans
Cells, Cultured
Dopaminergic Neurons - drug effects
Mesencephalon - drug effects
Mice
Neuroprotective Agents - pharmacology
Oxidopamine - toxicity
Rats
Withanolides - chemistry
Withanolides - pharmacology
Title Neuroprotective Effect of Withaferin Derivatives toward MPP+ and 6‑OHDA Toxicity to Dopaminergic Neurons
URI http://dx.doi.org/10.1021/acschemneuro.4c00655
https://www.ncbi.nlm.nih.gov/pubmed/39946298
https://www.proquest.com/docview/3166763592
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVABC
  databaseName: American Chemical Society Journals
  customDbUrl:
  eissn: 1948-7193
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0069086
  issn: 1948-7193
  databaseCode: ACS
  dateStart: 20100120
  isFulltext: true
  titleUrlDefault: https://pubs.acs.org/action/showPublications?display=journals
  providerName: American Chemical Society
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8QwEA66Xrz4fqwvIoggktWkTbo5Lq6yCD5ARW-lSVNcZbtiu6Ke_Av-RX-Jk7T1iaiX9hKmbTKZma-Z-QahNQkWEFTDEKVij_iUStLkQpOYB1pIpiOd2Grkg0PROfP3L_jFO1D8eoLP6FakAeaZnqN3bPja-kw-jEaYaFILtlo7J5XlBaDnOjsCLm-SACKTqlTuBynWIenss0P6Icp03mZvHB1VNTtFksl1Y5Crhn78TuH4xw-ZQGNl4IlbhaZMoiGTTqHpVgqgu_eA17FLBXX_2KfRlaPsKCkcwBziguMY9xN83s0vo8TWDOI2XO8cb3iGc5d9iw-OjzdxlMZYvDw9H3XaLXzav-9qiPRhBG4DQO-5YsOuxu4RaTaDzvZ2T3c6pGzKQCImg5wkxgRBRAXcZaBErLShyoI46TrieYElOJSUJwJCT8WTOJawHExxwzUHwOfNolraT808wrD7AU2BoERr3yhLSBpZijWtYrB627KONmDOwnJTZaE7L2c0_DiRYTmRdUSqVQxvCp6OX8avVksdwoaypyRRavqDLPSoTfv1uGR1NFfowJtEiOZ8wWRz4R9vtohGme0ZbPPW-BKq5bcDswyBTK5WnPa-Am2a8Ts
linkProvider American Chemical Society
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ZS8NAEB60PuiL91HPFUQQ2WqOTbqPxSr1qArW4y1kNxus0lRMKuqTf8G_6C9xdpt4gYgvCYRlssdk9pvszDcAaxwtIKqGokJEDnUti9Mq8ySNmC89bstQxjobuXnsNc7dgyt2NQCsyIXBTqQoKTWH-J_sAtYWPsNRdAzLY8WVeutkgzBkyFA0Ito5Kwww-numwCO651XqI0ApMuZ-kaL3JZl-35d-AZtm09kbg4uP7ppYk9tKLxMV-fyDyfHf4xmH0RyGklpfbyZgQCWTMFVL0AXvPJF1YgJDzR_3KbgxBB45oQMaR9JnPCbdmFy2s-sw1hmEpI7XB8MinpLMxOKS5unpJgmTiHhvL68njXqNtLqPbYm4H1uQOrrrHZN62JbEvCJJp-F8b7e106B5iQYa2tzPaKyU74eWh3fuCy8SUllCu3Tc1MdzfE13yC0WewhEBYujiOOq2IIpJhm6f84MlJJuouaAoC1A3woFxVK6Smh60lATrkkRoQ3c5mXYwDkL8k8sDczpuW0FXycyyCeyDLRYzOCuz9rxR_vVYsUD_Lz0mUmYqG4vDRxLBwE7jNtlmO2rwodExHauZ_Pq_D96tgLDjVbzKDjaPz5cgBFbVxPWEW1sEUrZfU8tIcTJxLJR6Het8vmm
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZS8NAEB48QHzxPuq5gggiW82xSfexWEu9CyqKLyG72WCVpsWkoj75F_yL_hJnt2mpgoi-JBDCZI_Z2W-yM98AbHK0gKgaigoROdS1LE5LzJM0Yr70uC1DGets5NMzr3blHt2wm4FSX9iIFCWl5hBfr-p2FOcMA9YuPseeNA3TY9GVevtkwzDKNAucRkX7Fz0jjD6fKfKILnqJ-ghSellzP0jRe5NMv-5NPwBOs_FUJ-G232QTb_JQ7GSiKF-_sTn-q09TMJHDUVLu6s80DKlkBmbLCbrizReyRUyAqPnzPgv3hsgjJ3ZAI0m6zMekFZPrRnYXxjqTkFTw-mTYxFOSmZhcclqv75AwiYj38fZ-XquUyWXruSER_-MbpIJue9OkIDYkMZ9I0jm4qh5c7tdoXqqBhjb3Mxor5fuh5eGd-8KLhFSW0K4dN3XyHF_THnKLxR4CUsHiKOI4M7ZgikmGbqAzDyNJK1GLQNAmoI-FgmIpXSU0TWmoidekiNAW7vECbOOYBflSSwNzim5bweBABvlAFoD2JjRod9k7fnl_ozfrAS4zfXYSJqrVSQPH0sHADuN2ARa66tCXiBjP9WxeWvpDy9ZhrF6pBieHZ8fLMG7rosI6sI2twEj22FGriHQysWZ0-hOXAPwg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Neuroprotective+Effect+of+Withaferin+Derivatives+toward+MPP%2B+and+6-OHDA+Toxicity+to+Dopaminergic+Neurons&rft.jtitle=ACS+chemical+neuroscience&rft.au=Parrales%2C+Valeria&rft.au=Arcile%2C+Guillaume&rft.au=Laserre%2C+Louise&rft.au=Normant%2C+S%C3%A9bastien&rft.date=2025-03-05&rft.issn=1948-7193&rft.eissn=1948-7193&rft.volume=16&rft.issue=5&rft.spage=802&rft_id=info:doi/10.1021%2Facschemneuro.4c00655&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1948-7193&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1948-7193&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1948-7193&client=summon